Top 5 Stock Picks of Eli Casdin’s Casdin Capital

4. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Casdin Capital’s Stake Value: $68,149,000
Percentage of Casdin Capital’s 13F Portfolio: 5.76%
Number of Hedge Fund Holders: 17

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine firm. Research & development costs of Relay Therapeutics, Inc. (NASDAQ:RLAY) were $60.5 million in the second quarter of 2022, up from $45.1 million in the same period the previous year. The company has five ongoing discovery projects, with three of them being cancer-related. Two more are for diseases that run in families.

Barclays analyst Peter Lawson initiated coverage on Relay Therapeutics, Inc. (NASDAQ:RLAY) on September 30, assigning the stock an ‘Equal Weight’ rating and a $23 price target. Biotechnology Value Fund / BVF Inc is Relay Therapeutics, Inc. (NASDAQ:RLAY)’s largest shareholder, with shares worth $73.45 million.

Casdin Capital owned 4.07 million shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) in the second quarter, worth $68.15 million and representing 5.76% of the fund’s total portfolio. The hedge fund elevated its position in Relay Therapeutics, Inc. (NASDAQ:RLAY) by 6% in Q2 2022.

According to Insider Monkey’s data, 17 hedge funds held stakes in Relay Therapeutics, Inc. (NASDAQ:RLAY) during the second quarter of 2022, collectively worth $349.36 million. This is down from 18 hedge funds in the preceding quarter with stakes worth $587.71 million in the company.

Follow Relay Therapeutics Inc. (NASDAQ:RLAY)